Abbott Laboratories (NYSE:ABT) Shares Bought by Coppell Advisory Solutions LLC

Coppell Advisory Solutions LLC lifted its position in shares of Abbott Laboratories (NYSE:ABT) by 5.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 23,923 shares of the healthcare product maker’s stock after buying an additional 1,147 shares during the period. Coppell Advisory Solutions LLC’s holdings in Abbott Laboratories were worth $2,699,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently added to or reduced their stakes in the company. T. Rowe Price Investment Management Inc. increased its position in shares of Abbott Laboratories by 383.1% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 8,358,698 shares of the healthcare product maker’s stock valued at $945,453,000 after acquiring an additional 6,628,310 shares during the last quarter. MGO One Seven LLC boosted its position in shares of Abbott Laboratories by 10.8% during the fourth quarter. MGO One Seven LLC now owns 22,293 shares of the healthcare product maker’s stock worth $2,522,000 after buying an additional 2,168 shares during the period. Quantessence Capital LLC purchased a new stake in shares of Abbott Laboratories in the 4th quarter valued at $496,000. Alta Advisers Ltd lifted its stake in Abbott Laboratories by 21.7% during the 4th quarter. Alta Advisers Ltd now owns 5,720 shares of the healthcare product maker’s stock worth $647,000 after acquiring an additional 1,020 shares in the last quarter. Finally, Fayez Sarofim & Co boosted its holdings in Abbott Laboratories by 11.6% during the 4th quarter. Fayez Sarofim & Co now owns 4,675,798 shares of the healthcare product maker’s stock valued at $532,859,000 after acquiring an additional 486,028 shares during the period. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Abbott Laboratories

In other news, EVP Andrea F. Wainer sold 949 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $138.17, for a total transaction of $131,123.33. Following the completion of the sale, the executive vice president now owns 74,381 shares in the company, valued at $10,277,222.77. This represents a 1.26 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Eric Shroff sold 562 shares of Abbott Laboratories stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $138.17, for a total transaction of $77,651.54. Following the completion of the transaction, the senior vice president now owns 31,970 shares in the company, valued at approximately $4,417,294.90. This trade represents a 1.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 116,449 shares of company stock worth $15,463,316. 0.46% of the stock is owned by insiders.

Analysts Set New Price Targets

Several analysts have recently issued reports on ABT shares. Barclays increased their price target on shares of Abbott Laboratories from $158.00 to $159.00 and gave the stock an “overweight” rating in a research report on Thursday, April 17th. The Goldman Sachs Group raised their price target on shares of Abbott Laboratories from $138.00 to $154.00 and gave the company a “buy” rating in a research report on Tuesday, March 4th. Jefferies Financial Group increased their price objective on Abbott Laboratories from $135.00 to $137.00 and gave the company a “hold” rating in a research note on Thursday, April 17th. Raymond James boosted their target price on Abbott Laboratories from $132.00 to $142.00 and gave the stock an “outperform” rating in a research note on Thursday, April 17th. Finally, Argus raised Abbott Laboratories to a “strong-buy” rating in a research report on Tuesday, January 28th. Four investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $142.59.

Abbott Laboratories Stock Up 1.5 %

Shares of NYSE:ABT opened at $131.81 on Wednesday. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32. The firm has a 50 day simple moving average of $130.61 and a 200-day simple moving average of $122.15. The company has a market capitalization of $228.60 billion, a PE ratio of 17.23, a P/E/G ratio of 2.52 and a beta of 0.80. Abbott Laboratories has a twelve month low of $99.71 and a twelve month high of $141.23.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share for the quarter, beating analysts’ consensus estimates of $1.07 by $0.02. The firm had revenue of $10.36 billion during the quarter, compared to analysts’ expectations of $10.38 billion. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. On average, equities analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Shareholders of record on Tuesday, April 15th will be given a dividend of $0.59 per share. This represents a $2.36 annualized dividend and a yield of 1.79%. The ex-dividend date is Tuesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 30.61%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.